Harbin Pharmaceutical Group Co (600664.SS) Stock Price

Harbin Pharmaceutical Group Co Price

SSE·CLOSED
8.91CNY+0.05 (+0.56 %)
Market closed

Revenue has compounded at 3.4% per year over the past 19 years to 16.18 B CNY. Earnings per share have grown at 0.7% per year over the last 19 years. Harbin Pharmaceutical Group Co's net margin stands at 3.9%, up from -10.0% several years earlier. Harbin Pharmaceutical Group Co currently offers a dividend yield of about 5.61%. The payout ratio is around 357% of earnings. The dividend has grown at 17.5% per year over the past 10 years. Analysts set a median price target of 4.71 CNY, implying 47.1% below the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 204% above its 52-week low.

Harbin Pharmaceutical Group Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Harbin Pharmaceutical Group Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Harbin Pharmaceutical Group Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Harbin Pharmaceutical Group Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Harbin Pharmaceutical Group Co Stock Price History
DateHarbin Pharmaceutical Group Co Price
8/14/20268.91 CNY
8/13/20268.86 CNY
8/12/20268.60 CNY
8/11/20268.27 CNY
8/10/20267.52 CNY
8/7/20266.84 CNY
8/6/20266.22 CNY
8/5/20266.53 CNY
8/4/20266.45 CNY
8/3/20265.99 CNY
7/31/20265.89 CNY
7/30/20265.49 CNY
7/29/20265.36 CNY
7/28/20265.74 CNY
7/27/20265.64 CNY
7/24/20265.40 CNY
7/23/20266.04 CNY
7/22/20265.98 CNY
7/21/20265.84 CNY
7/20/20265.31 CNY
7/17/20264.96 CNY
7/16/20264.94 CNY
7/15/20264.49 CNY
7/14/20264.08 CNY
7/13/20263.71 CNY
7/10/20263.37 CNY
7/9/20263.06 CNY
7/8/20263.09 CNY
7/7/20263.07 CNY
7/6/20263.18 CNY
7/3/20263.13 CNY
7/2/20263.11 CNY
7/1/20263.09 CNY
6/30/20262.99 CNY
6/29/20263.08 CNY
6/26/20262.93 CNY
6/25/20263.01 CNY
6/24/20263.12 CNY
6/23/20263.19 CNY
6/22/20263.00 CNY
6/18/20263.08 CNY
6/17/20263.06 CNY
6/16/20263.13 CNY
6/15/20263.16 CNY
6/12/20263.17 CNY
6/11/20263.06 CNY
6/10/20263.11 CNY
6/9/20263.10 CNY
6/8/20263.11 CNY
6/5/20263.21 CNY
6/4/20263.17 CNY
6/3/20263.28 CNY
6/2/20263.33 CNY
6/1/20263.36 CNY
5/29/20263.36 CNY
5/28/20263.27 CNY
5/27/20263.26 CNY
5/26/20263.36 CNY
5/25/20263.40 CNY
5/22/20263.38 CNY
5/21/20263.43 CNY
5/20/20263.46 CNY
5/19/20263.55 CNY
5/18/20263.53 CNY
5/15/20263.64 CNY
5/14/20263.68 CNY
5/13/20263.88 CNY
5/12/20263.89 CNY
5/11/20264.01 CNY
5/8/20263.76 CNY
5/7/20263.66 CNY
5/6/20263.62 CNY
4/30/20263.58 CNY
4/29/20263.68 CNY
4/28/20263.69 CNY
4/27/20263.67 CNY
4/24/20263.70 CNY
4/23/20263.88 CNY
4/22/20263.93 CNY
4/21/20264.10 CNY
4/20/20264.28 CNY
4/17/20264.17 CNY
4/16/20264.40 CNY
4/15/20264.44 CNY
4/14/20264.04 CNY
4/13/20263.67 CNY
4/10/20263.76 CNY
4/9/20263.75 CNY
4/8/20263.74 CNY
4/7/20263.87 CNY
4/3/20263.52 CNY
4/2/20263.60 CNY
4/1/20263.59 CNY
3/31/20263.52 CNY
3/30/20263.45 CNY
3/27/20263.41 CNY
3/26/20263.33 CNY
3/25/20263.34 CNY
3/24/20263.31 CNY
3/23/20263.23 CNY
3/20/20263.44 CNY
3/19/20263.49 CNY
3/18/20263.57 CNY
3/17/20263.59 CNY
3/16/20263.58 CNY
3/13/20263.59 CNY
3/12/20263.59 CNY
3/11/20263.60 CNY
3/10/20263.59 CNY
3/9/20263.63 CNY
3/6/20263.50 CNY
3/5/20263.45 CNY
2/27/20263.53 CNY
2/26/20263.51 CNY
2/25/20263.51 CNY
2/13/20263.45 CNY
2/12/20263.53 CNY
2/11/20263.54 CNY
2/10/20263.53 CNY
2/9/20263.53 CNY
2/6/20263.52 CNY
2/5/20263.52 CNY
2/4/20263.52 CNY
2/3/20263.48 CNY
2/2/20263.46 CNY
1/30/20263.52 CNY
1/29/20263.53 CNY
1/28/20263.54 CNY
1/27/20263.55 CNY
1/26/20263.60 CNY
1/23/20263.57 CNY
1/22/20263.53 CNY
1/21/20263.52 CNY
1/20/20263.53 CNY
1/19/20263.51 CNY
1/16/20263.51 CNY
1/15/20263.51 CNY
1/14/20263.55 CNY
1/13/20263.57 CNY
1/12/20263.56 CNY
1/9/20263.54 CNY
1/8/20263.50 CNY
1/7/20263.50 CNY
1/6/20263.53 CNY
1/5/20263.51 CNY
12/31/20253.46 CNY
12/30/20253.49 CNY
12/29/20253.49 CNY
12/26/20253.53 CNY
12/25/20253.55 CNY
12/24/20253.55 CNY
12/23/20253.54 CNY
12/22/20253.59 CNY
12/19/20253.59 CNY
12/18/20253.54 CNY
12/17/20253.55 CNY
12/16/20253.52 CNY
12/15/20253.56 CNY
12/12/20253.57 CNY
12/11/20253.58 CNY
12/10/20253.66 CNY
12/9/20253.65 CNY
12/8/20253.71 CNY
12/5/20253.75 CNY
12/4/20253.71 CNY
12/3/20253.71 CNY
12/2/20253.64 CNY
12/1/20253.62 CNY
11/28/20253.60 CNY
11/27/20253.65 CNY
11/26/20253.68 CNY
11/25/20253.61 CNY
11/24/20253.55 CNY
11/21/20253.53 CNY
11/20/20253.68 CNY
11/19/20253.68 CNY
11/18/20253.76 CNY
11/17/20253.83 CNY
11/14/20253.90 CNY
11/13/20253.80 CNY
11/12/20253.76 CNY
11/11/20253.77 CNY
11/10/20253.74 CNY
11/7/20253.70 CNY
11/6/20253.68 CNY
11/5/20253.70 CNY
11/4/20253.67 CNY
11/3/20253.68 CNY
10/31/20253.65 CNY
10/30/20253.64 CNY
10/29/20253.65 CNY
10/28/20253.64 CNY
10/27/20253.68 CNY
10/24/20253.71 CNY
10/23/20253.73 CNY
10/22/20253.77 CNY
10/21/20253.73 CNY
10/20/20253.67 CNY
10/17/20253.64 CNY
10/16/20253.64 CNY
10/15/20253.65 CNY
10/14/20253.61 CNY
10/13/20253.61 CNY
10/10/20253.64 CNY
10/9/20253.60 CNY
9/30/20253.58 CNY
9/29/20253.60 CNY
9/26/20253.60 CNY
9/25/20253.55 CNY
9/24/20253.58 CNY
9/23/20253.56 CNY
9/22/20253.61 CNY
9/19/20253.66 CNY
9/18/20253.68 CNY
9/17/20253.71 CNY
9/16/20253.71 CNY
9/15/20253.70 CNY
9/12/20253.72 CNY
9/11/20253.71 CNY
9/10/20253.69 CNY
9/9/20253.70 CNY
9/8/20253.73 CNY
9/5/20253.71 CNY
9/4/20253.70 CNY
9/3/20253.68 CNY
9/2/20253.72 CNY
9/1/20253.74 CNY
8/29/20253.73 CNY
8/28/20253.74 CNY
8/27/20253.78 CNY
8/26/20253.89 CNY
8/25/20253.92 CNY
8/22/20254.04 CNY
8/21/20254.03 CNY
8/20/20254.01 CNY
8/19/20254.00 CNY
8/18/20253.96 CNY
Access this data via the Eulerpool API
Get Free API Key

Harbin Pharmaceutical Group Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
12.80 B CNY
520.13 M CNY
371.08 M CNY
Jan 1, 2022
13.81 B CNY
600.14 M CNY
464.36 M CNY
Jan 1, 2023
15.46 B CNY
683.68 M CNY
395.26 M CNY
Jan 1, 2024
16.18 B CNY
965.30 M CNY
628.85 M CNY
Jan 1, 2025 (e)
18.17 B CNY
875.22 M CNY
654.81 M CNY
Jan 1, 2026 (e)
16.40 B CNY
790.07 M CNY
453.33 M CNY
Jan 1, 2027 (e)
16.94 B CNY
815.88 M CNY
528.89 M CNY
Jan 1, 2028 (e)
17.49 B CNY
842.47 M CNY
604.44 M CNY

Harbin Pharmaceutical Group Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 10:46 AM
 
REVENUEB CNY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB CNY
EBITB CNY
EBIT MARGIN%
NET INCOMEB CNY
NET INCOME GROWTH%
DIV.CNY
DIV. GROWTH%
SHARESB
2013201420152016201720182019202020212022202320242025e2026e2027e2028e
18.0916.5115.8614.1312.0210.8111.8310.7912.8013.8115.4616.1818.1716.4016.9417.49
2.43-8.75-3.96-10.90-14.93-10.029.35-8.7718.677.8611.944.6512.34-9.733.273.26
29.2727.0324.4226.2025.8926.7823.7220.9123.3024.4126.0227.9927.9927.9927.9927.99
5.304.463.873.703.112.902.812.262.983.374.024.535.094.594.744.90
0.260.340.740.940.550.510.19-0.880.520.600.680.970.880.790.820.84
1.422.084.656.634.534.731.59-8.114.064.354.425.974.824.824.814.81
0.170.250.580.790.410.350.06-1.080.370.460.400.630.650.450.530.60
-66.2046.15134.8235.86-48.35-14.99-83.82-2,025.00-134.4225.07-14.8758.994.14-30.7316.5614.39
–0.101.54–1.000.50––––––0.600.720.86–
––1,440.00––-50.00–––––––20.0019.44–
2.492.492.492.542.552.552.512.512.472.582.472.522.522.522.522.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Harbin Pharmaceutical Group Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Harbin Pharmaceutical Group Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Harbin Pharmaceutical Group Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Harbin Pharmaceutical Group Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Harbin Pharmaceutical Group Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Harbin Pharmaceutical Group Co stock margins

The Harbin Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Harbin Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Harbin Pharmaceutical Group Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
20.91 %
-8.11 %
-9.99 %
Jan 1, 2021
23.31 %
4.06 %
2.90 %
Jan 1, 2022
24.41 %
4.35 %
3.36 %
Jan 1, 2023
26.02 %
4.42 %
2.56 %
Jan 1, 2024
27.99 %
5.97 %
3.89 %
Jan 1, 2025 (e)
27.99 %
4.82 %
3.60 %
Jan 1, 2026 (e)
27.99 %
4.82 %
2.76 %
Jan 1, 2027 (e)
27.99 %
4.82 %
3.12 %

Harbin Pharmaceutical Group Co Stock Revenue, EBIT, Earnings per Share

The Harbin Pharmaceutical Group Co earnings per share therefore indicates how much revenue Harbin Pharmaceutical Group Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
4.30 CNY
-0.35 CNY
-0.43 CNY
Jan 1, 2021
5.17 CNY
0.21 CNY
0.15 CNY
Jan 1, 2022
5.35 CNY
0.23 CNY
0.18 CNY
Jan 1, 2023
6.26 CNY
0.28 CNY
0.16 CNY
Jan 1, 2024
6.42 CNY
0.38 CNY
0.25 CNY
Jan 1, 2025 (e)
7.21 CNY
0.35 CNY
0.26 CNY
Jan 1, 2026 (e)
6.51 CNY
0.31 CNY
0.18 CNY
Jan 1, 2027 (e)
6.73 CNY
0.32 CNY
0.21 CNY

Harbin Pharmaceutical Group Co business model & stock analysis

Harbin Pharmaceutical Group Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Harbin Pharmaceutical Group Co historical P/E ratio, EBIT multiple, and P/S ratio

Harbin Pharmaceutical Group Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Harbin Pharmaceutical Group Co shares outstanding

The number of shares of Harbin Pharmaceutical Group Co was 2.52 B in 2025. This indicates how many shares Harbin Pharmaceutical Group Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
2.51 B Stocks
Jan 1, 2021
2.47 B Stocks
Jan 1, 2022
2.58 B Stocks
Jan 1, 2023
2.47 B Stocks
Jan 1, 2024
2.52 B Stocks
Jan 1, 2025 (e)
2.52 B Stocks
Jan 1, 2026 (e)
2.52 B Stocks
Jan 1, 2027 (e)
2.52 B Stocks

Harbin Pharmaceutical Group Co stock splits

In Harbin Pharmaceutical Group Co's history, there have been no stock splits.

Harbin Pharmaceutical Group Co Dividend History

17 years of dividend payments

YearAnnual DividendYoY ChangePayments
20180.50CNY 0.0%1×
20170.50CNY↓ 50.0%1×
20151.00CNY↑ 1,415.2%1×
20140.07CNY↓ 85.2%1×
20110.45CNY↓ 8.9%1×
20100.49CNY↓ 16.9%1×
20090.59CNY↑ 490.0%1×
20080.10CNY 0.0%1×
20040.10CNY↓ 16.7%1×
20030.12CNY↑ 20.0%1×

Harbin Pharmaceutical Group Co dividend history and estimates

In 2025, Harbin Pharmaceutical Group Co paid a dividend amounting to 0.60 CNY. Dividend means that Harbin Pharmaceutical Group Co distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2011
0.45 CNY
0.00 CNY
Jan 1, 2014 (e)
0.07 CNY
0.04 CNY
Jan 1, 2015 (e)
1.00 CNY
0.54 CNY
Jan 1, 2017 (e)
0.50 CNY
0.50 CNY
Jan 1, 2018
0.50 CNY
0.00 CNY
Jan 1, 2025 (e)
0.00 CNY
0.60 CNY
Jan 1, 2026 (e)
0.00 CNY
0.72 CNY
Jan 1, 2027 (e)
0.00 CNY
0.86 CNY

Harbin Pharmaceutical Group Co dividend payout ratio

In 2025, Harbin Pharmaceutical Group Co had a payout ratio of 230.77%. The payout ratio indicates the percentage of the company's profits that Harbin Pharmaceutical Group Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
334.81 %
Jan 1, 2021
342.24 %
Jan 1, 2022
337.28 %
Jan 1, 2023
338.11 %
Jan 1, 2024
339.21 %
Jan 1, 2025 (e)
230.77 %
Jan 1, 2026 (e)
400.00 %
Jan 1, 2027 (e)
411.43 %

Current Harbin Pharmaceutical Group Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
4.71
Last Price
8.91
Currency
CNY
12M Return Potential
-47.11 %
LTM Return
0 %

Harbin Pharmaceutical Group Co shareholder structure

% Name
0.21252%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.16004%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.02036%
Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V.
0.01699%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.
0.00150%
Vanguard Global Advisers LLC
Vanguard Global Advisers LLC
0.00065%
Vanguard Investments Australia Ltd.
Vanguard Investments Australia Ltd.

Harbin Pharmaceutical Group Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
52.1%
Float Shares
-
Shares Outstanding
-

Harbin Pharmaceutical Group Co Executives and Management Board

15 members · avg. age 52 · 33 % women

CL

Mr. Chuanyou Lu (61)

President, Director · since 2021

1.39 M CNY

Management

BL

Mr. Bo Liu (61)

Finance Director, Vice President · since 2008

1.19 M CNY
XM

Mr. Xiaodong Meng (50)

Vice President, Secretary of the Board

1.14 M CNY
HJ

Mr. Haitao Jiang (42)

Vice President

982,500.00 CNY
JX

Mr. Jicheng Xia (45)

Vice President

756,200.00 CNY
BL

Mr. Bangdong Li (51)

Vice President

752,500.00 CNY
GD

Mr. Guangjun Diao (49)

Vice President

–

Board of Directors

ZL

Ms. Zhaohua Li (58)

Independent Director

150,000.00 CNY
AL

Ms. Aidong Lou (58)

Independent Director

150,000.00 CNY
WL

Ms. Weihong Lu (54)

Independent Director

150,000.00 CNY
XH

Ms. Xiaoping Hu (54)

Chairman of the Board · since 2021

–
ML

Mr. Mo Liu (45)

Director

–
ZS

Mr. Zhifeng Sun (43)

Director

–

Frequently asked questions about Harbin Pharmaceutical Group Co

Analysts currently set an average price target of 4.71 CNY for the Harbin Pharmaceutical Group Co stock (median: 4.71 CNY), implying -47.1 % versus the latest price. The consensus is based on 5 analyst ratings.

Harbin Pharmaceutical Group Co Analyst Price Targets 2026

5 analysts currently rate the Harbin Pharmaceutical Group Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Harbin Pharmaceutical Group Co to generate revenue of 16.40 B CNY and earnings per share of 0.18 CNY.

Harbin Pharmaceutical Group Co Analyst Price Targets 2026

Converted at the current exchange rate, the Harbin Pharmaceutical Group Co share trades at 1.14 EUR (8.91 CNY).

No history available for Harbin Pharmaceutical Group Co.

The expected revenue of Harbin Pharmaceutical Group Co is 16.40 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Harbin Pharmaceutical Group Co is 453.33 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Harbin Pharmaceutical Group Co is currently 49.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Harbin Pharmaceutical Group Co stock.

The price-to-sales ratio (P/S) of Harbin Pharmaceutical Group Co is currently 1.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Harbin Pharmaceutical Group Co stock.

The Eulerpool Quality Score for Harbin Pharmaceutical Group Co is 4/10.

The ISIN of Harbin Pharmaceutical Group Co is CNE0000009T3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Harbin Pharmaceutical Group Co is 600664.SS. The ticker symbol is used to trade Harbin Pharmaceutical Group Co shares on the stock exchange.

Over the past 12 months, Harbin Pharmaceutical Group Co paid a dividend of 0.50 CNY . This corresponds to a dividend yield of about 5.61 %. For the coming 12 months, Harbin Pharmaceutical Group Co is expected to pay a dividend of 0.86 CNY.

The current dividend yield of Harbin Pharmaceutical Group Co is 5.61 %.

Harbin Pharmaceutical Group Co pays a dividend, distributed in the months of , , , .

Harbin Pharmaceutical Group Co paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.86 CNY are expected. This corresponds to a dividend yield of 9.70 %.

Harbin Pharmaceutical Group Co is assigned to the 'Health' sector.

To receive the latest dividend of Harbin Pharmaceutical Group Co from amounting to 0.5 CNY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Harbin Pharmaceutical Group Co are distributed in CNY.

All fundamentals and in-depth analysis of Harbin Pharmaceutical Group Co

Our stock analysis for Harbin Pharmaceutical Group Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harbin Pharmaceutical Group Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Revenue→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Net Income→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co P/E→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co P/S→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co EBIT→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Dividend→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Directors Dealings→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Stocks→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Market capitalization→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Debt→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Liabilities→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Equity→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co AAQS→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Employees→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co ROE→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co ROA→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co ROCE→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co News→
Harbin Pharmaceutical Group Co Stock
Harbin Pharmaceutical Group Co Analyst Price Targets→

Health Stocks

Harbor DiversifiedHarbin Medisan Pharmaceutical CoHarmony Biosciences HoldingsHARBIN GLORIA PHARMACEUTICALS CoHarrowHarbin Fuerjia Technology CoHarvard Apparatus Regenerative TechnologyHapvida Participacoes e InvestimentosHarvard BioscienceHansoh Pharmaceutical Group CompanyHassHanshang Group CoAll Stocks A–Z →